The Summary
This retrospective cohort study analyzed claims data from 21,250 overweight or obese adults with established cardiovascular disease, but without diabetes, to compare the heart benefits of semaglutide and tirzepatide. Researchers matched patients and tracked major adverse cardiovascular events (MACE), including heart attacks, strokes, and mortality. The findings revealed that semaglutide was associated with a 29% lower risk of 3-point MACE and a 22% lower risk of 5-point MACE compared to tirzepatide. These results suggest semaglutide may offer superior early cardiovascular protection in this specific patient population.
Why this is interesting
While both semaglutide and tirzepatide are highly effective for obesity, their impacts on heart health are still being compared. Previously, clinical trials proved semaglutide reduces heart attacks and strokes, leading to its FDA approval for this use. This real-world analysis suggests semaglutide might offer significantly better protection against major heart events than tirzepatide for people with a history of cardiovascular disease. For readers managing heart conditions, this highlights that not all GLP-1 medications are identical, making semaglutide a potentially stronger option for prioritizing cardiovascular health.